| scholarly article | Q13442814 |
| P2093 | author name string | Sang-Moo Kang | |
| Jong Seok Lee | |||
| Hye Suk Hwang | |||
| Min-Chul Kim | |||
| Yu-Na Lee | |||
| Young-Tae Lee | |||
| Martin L Moore | |||
| P2860 | cites work | Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice | Q44880088 |
| Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice | Q45353370 | ||
| The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans | Q45420643 | ||
| Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial | Q45458064 | ||
| Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants | Q45504141 | ||
| Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. | Q45722558 | ||
| Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine | Q45734744 | ||
| Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. | Q45746795 | ||
| Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis | Q45769900 | ||
| A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. | Q45776569 | ||
| Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization | Q45849864 | ||
| Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice | Q45868048 | ||
| Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee | Q45868590 | ||
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
| Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry | Q24657793 | ||
| Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes | Q27668015 | ||
| Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis | Q29619821 | ||
| A DNA transfection system for generation of influenza A virus from eight plasmids | Q29642855 | ||
| Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus | Q30334543 | ||
| Immune responses to influenza virus infection | Q30407654 | ||
| Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus | Q30441455 | ||
| Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity | Q33908690 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents | Q34222406 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats | Q34506016 | ||
| Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines | Q35629114 | ||
| Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice | Q36106575 | ||
| Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains | Q36363325 | ||
| An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice | Q36500189 | ||
| Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice | Q36667922 | ||
| Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. | Q36993991 | ||
| Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. | Q37147650 | ||
| Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity | Q37401975 | ||
| Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. | Q37492531 | ||
| A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. | Q37627348 | ||
| Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease | Q37649439 | ||
| Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation | Q37690464 | ||
| Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. | Q37713874 | ||
| Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model | Q37713960 | ||
| Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice | Q39025841 | ||
| Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion | Q39697277 | ||
| Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract | Q40158643 | ||
| A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees | Q41458369 | ||
| Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. | Q41482419 | ||
| Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. | Q42235080 | ||
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2014-12-13 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease | |
| P478 | volume | 115 |
| Q38905050 | A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge |
| Q40664205 | Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. |
| Q90168333 | Identification of a human respiratory syncytial virus phosphoprotein domain required for virus-like-particle formation |
| Q38830323 | Multivalent and Multipathogen Viral Vector Vaccines |
| Q36739674 | Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin |
| Q37189330 | Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination |
| Q104756334 | Tetramerization of Phosphoprotein is Essential for Respiratory Syncytial Virus Budding while its N Terminal Region Mediates Direct Interactions with the Matrix Protein |
| Q116166800 | Tetramerization of Phosphoprotein is essential for Respiratory Syncytial virus budding while its N terminal region mediates direct interactions with the Matrix protein |
Search more.